313 related articles for article (PubMed ID: 21422926)
1. Mouse models of diabetic nephropathy.
Alpers CE; Hudkins KL
Curr Opin Nephrol Hypertens; 2011 May; 20(3):278-84. PubMed ID: 21422926
[TBL] [Abstract][Full Text] [Related]
2. BTBR Ob/Ob mutant mice model progressive diabetic nephropathy.
Hudkins KL; Pichaiwong W; Wietecha T; Kowalewska J; Banas MC; Spencer MW; Mühlfeld A; Koelling M; Pippin JW; Shankland SJ; Askari B; Rabaglia ME; Keller MP; Attie AD; Alpers CE
J Am Soc Nephrol; 2010 Sep; 21(9):1533-42. PubMed ID: 20634301
[TBL] [Abstract][Full Text] [Related]
3. A new mouse model resembling human diabetic nephropathy: uncoupling of VEGF with eNOS as a novel pathogenic mechanism.
Nakagawa T
Clin Nephrol; 2009 Feb; 71(2):103-9. PubMed ID: 19203501
[TBL] [Abstract][Full Text] [Related]
4. Beneficial effect on podocyte number in experimental diabetic nephropathy resulting from combined atrasentan and RAAS inhibition therapy.
Hudkins KL; Wietecha TA; Steegh F; Alpers CE
Am J Physiol Renal Physiol; 2020 May; 318(5):F1295-F1305. PubMed ID: 32249614
[TBL] [Abstract][Full Text] [Related]
5. The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2 diabetic mice with and without hypertension.
Gembardt F; Bartaun C; Jarzebska N; Mayoux E; Todorov VT; Hohenstein B; Hugo C
Am J Physiol Renal Physiol; 2014 Aug; 307(3):F317-25. PubMed ID: 24944269
[TBL] [Abstract][Full Text] [Related]
6. Reversibility of structural and functional damage in a model of advanced diabetic nephropathy.
Pichaiwong W; Hudkins KL; Wietecha T; Nguyen TQ; Tachaudomdach C; Li W; Askari B; Kobayashi T; O'Brien KD; Pippin JW; Shankland SJ; Alpers CE
J Am Soc Nephrol; 2013 Jun; 24(7):1088-102. PubMed ID: 23641056
[TBL] [Abstract][Full Text] [Related]
7. Effects of CP-900691, a novel peroxisome proliferator-activated receptor α, agonist on diabetic nephropathy in the BTBR ob/ob mouse.
Askari B; Wietecha T; Hudkins KL; Fox EJ; O'Brien KD; Kim J; Nguyen TQ; Alpers CE
Lab Invest; 2014 Aug; 94(8):851-62. PubMed ID: 24955894
[TBL] [Abstract][Full Text] [Related]
8. Regression of diabetic nephropathy by treatment with empagliflozin in BTBR ob/ob mice.
Hudkins KL; Li X; Holland AL; Swaminathan S; Alpers CE
Nephrol Dial Transplant; 2022 Apr; 37(5):847-859. PubMed ID: 34865099
[TBL] [Abstract][Full Text] [Related]
9. Comparison of diabetic nephropathy between male and female eNOS
Ma Y; Li W; Yazdizadeh Shotorbani P; Dubansky BH; Huang L; Chaudhari S; Wu P; Wang LA; Ryou MG; Zhou Z; Ma R
Am J Physiol Renal Physiol; 2019 May; 316(5):F889-F897. PubMed ID: 30810354
[TBL] [Abstract][Full Text] [Related]
10. Mouse models of diabetic nephropathy.
Brosius FC; Alpers CE; Bottinger EP; Breyer MD; Coffman TM; Gurley SB; Harris RC; Kakoki M; Kretzler M; Leiter EH; Levi M; McIndoe RA; Sharma K; Smithies O; Susztak K; Takahashi N; Takahashi T;
J Am Soc Nephrol; 2009 Dec; 20(12):2503-12. PubMed ID: 19729434
[TBL] [Abstract][Full Text] [Related]
11. Nicorandil as a novel therapy for advanced diabetic nephropathy in the eNOS-deficient mouse.
Tanabe K; Lanaspa MA; Kitagawa W; Rivard CJ; Miyazaki M; Klawitter J; Schreiner GF; Saleem MA; Mathieson PW; Makino H; Johnson RJ; Nakagawa T
Am J Physiol Renal Physiol; 2012 May; 302(9):F1151-60. PubMed ID: 22338086
[TBL] [Abstract][Full Text] [Related]
12. Endothelial nitric oxide synthase.
Nakagawa T; Johnson RJ
Contrib Nephrol; 2011; 170():93-101. PubMed ID: 21659762
[TBL] [Abstract][Full Text] [Related]
13. Endothelial nitric oxide synthase deficiency produces accelerated nephropathy in diabetic mice.
Zhao HJ; Wang S; Cheng H; Zhang MZ; Takahashi T; Fogo AB; Breyer MD; Harris RC
J Am Soc Nephrol; 2006 Oct; 17(10):2664-9. PubMed ID: 16971655
[TBL] [Abstract][Full Text] [Related]
14. Diabetic endothelial nitric oxide synthase knockout mice develop advanced diabetic nephropathy.
Nakagawa T; Sato W; Glushakova O; Heinig M; Clarke T; Campbell-Thompson M; Yuzawa Y; Atkinson MA; Johnson RJ; Croker B
J Am Soc Nephrol; 2007 Feb; 18(2):539-50. PubMed ID: 17202420
[TBL] [Abstract][Full Text] [Related]
15. Carnosine Attenuates the Development of both Type 2 Diabetes and Diabetic Nephropathy in BTBR ob/ob Mice.
Albrecht T; Schilperoort M; Zhang S; Braun JD; Qiu J; Rodriguez A; Pastene DO; Krämer BK; Köppel H; Baelde H; de Heer E; Anna Altomare A; Regazzoni L; Denisi A; Aldini G; van den Born J; Yard BA; Hauske SJ
Sci Rep; 2017 Mar; 7():44492. PubMed ID: 28281693
[TBL] [Abstract][Full Text] [Related]
16. Deficiency of endothelial nitric-oxide synthase confers susceptibility to diabetic nephropathy in nephropathy-resistant inbred mice.
Kanetsuna Y; Takahashi K; Nagata M; Gannon MA; Breyer MD; Harris RC; Takahashi T
Am J Pathol; 2007 May; 170(5):1473-84. PubMed ID: 17456755
[TBL] [Abstract][Full Text] [Related]
17. Chronic hypoxia exacerbates diabetic glomerulosclerosis through mesangiolysis and podocyte injury in db/db mice.
Takahashi N; Yoshida H; Kimura H; Kamiyama K; Kurose T; Sugimoto H; Imura T; Yokoi S; Mikami D; Kasuno K; Kurosawa H; Hirayama Y; Naiki H; Hara M; Iwano M
Nephrol Dial Transplant; 2020 Oct; 35(10):1678-1688. PubMed ID: 32596728
[TBL] [Abstract][Full Text] [Related]
18. Recent advances in animal models of diabetic nephropathy.
Betz B; Conway BR
Nephron Exp Nephrol; 2014; 126(4):191-5. PubMed ID: 25034792
[TBL] [Abstract][Full Text] [Related]
19. Pathology identifies glomerular treatment targets in diabetic nephropathy.
Alpers CE; Hudkins KL
Kidney Res Clin Pract; 2018 Jun; 37(2):106-111. PubMed ID: 29971205
[TBL] [Abstract][Full Text] [Related]
20. Endothelial cell-specific overexpression of endothelial nitric oxide synthase in Ins2Akita mice exacerbates diabetic nephropathy.
Natarajan M; Habib SL; Reddick RL; Delma CR; Manickam K; Prihoda TJ; Werner SL; Mohan S
J Diabetes Complications; 2019 Jan; 33(1):23-32. PubMed ID: 30424931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
